Development of an LC-MS/MS method to simultaneously quantify therapeutic mAbs and estimate hematocrit values in dried blood spot samples
Chiu et al.
The finding, in our words
An LC-MS/MS method for dried blood spots simultaneously quantifies four therapeutic monoclonal antibodies and estimates haematocrit from haemoglobin peptides with >0.9 correlation to laboratory values, enabling accurate therapeutic drug monitoring from self-collected samples for decentralised care.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
The HematoCARD cartridge autonomously collects duplicate 10 microlitre dried blood spot samples from a single finger prick and shows good analytical performance for monitoring adalimumab, with accuracy between 91 and 111 per cent, linearity R squared 0.99 and coefficient of variation at or above 0.94 compared with serum reference and commercial DBS microsampling methods.
Van Hileghem et al., Analytical chemistry (paywalled) · source ↗
Microsampling reduces sample volume, invasiveness, logistics and biohazard risk while improving stability and enabling at-home self-sampling, yet clinical adoption remains slow and requires standardisation and harmonisation to realise its patient-centric and decentralised potential.
Thangavelu et al., Analytical science advances · source ↗
An IQ Consortium position paper from sponsor scientists positioning patient-centric sampling as the enabling technology for decentralised trials, and stating that a bridging study against conventional sampling “has quickly been established as a regulatory expectation”.
Maass et al., Clinical and Translational Science · source ↗
A microfluidic DBS device using hydrophobic burst valves meters 5-15 μL blood accurately across 25-70% haematocrit and, in a therapeutic drug monitoring validation with adalimumab-spiked samples, achieves higher recovery than traditional DBS (86% versus 62%), supporting precise home or low-resource sampling.
Vloemans et al., Lab on a chip (paywalled) · source ↗
In AML and CLL, 91% of VAMS venetoclax results fell within 20% of plasma after individualised haematocrit correction; in home sampling, 18 of 21 patients self-sampled independently and 76% of returned samples were analysable, which shows home microsampling is workable, though the authors ask for multicentre validation.
Levens et al., Clinical Pharmacokinetics (paywalled) · source ↗